Immunome (IMNM) Stock Statistics & Valuation Metrics

Immunome has a market cap or net worth of $2.40B. The enterprise value is $1.88B.

Market Cap

$2.40B

Enterprise Value

$1.88B

Immunome has 118,003,110 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

118,003,110

Owned by Insiders

1.45%

Owned by Institutions

51.50%

Immunome’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -33.55%.

Return on Equity (ROE)

-0.33

Return on Assets (ROA)

-0.31

Return on Invested Capital (ROIC)

-33.55%

Return on Capital Employed (ROCE)

-0.34

Revenue Per Employee

28.10K

Profits Per Employee

-859.89K

Employee Count

247

Asset Turnover

0.01

Inventory Turnover

0.00

The current PE Ratio of Immunome is -7.69. Immunome’s PEG ratio is -0.46.

PE Ratio

-7.69

PS Ratio

0.00

PB Ratio

4.21

Price to FCF

-10.51

Price to Operating Cash Flow

-10.59

PEG Ratio

-0.46

In the last 12 months, Immunome had revenue of 6.94M and earned -212.39M in profits. Earnings per share was -2.43.

Revenue

6.94M

Gross Profit

3.99M

Operating Income

-214.11M

Pretax Income

-212.39M

Net Income

-212.39M

EBITDA

-209.44M

Earnings Per Share (EPS)

-2.43

In the last 12 months, operating cash flow was -208.79M and capital expenditures -10.29M, giving a free cash flow of -219.09M billion.

Operating Cash Flow

-208.79M

Free Cash Flow

-219.09M

Free Cash Flow per Share

-1.93

Immunome pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-9.51%

Earnings Yield

-11.50%

Beta

1.61

52-Week Price Change

26.67%

50-Day Moving Average

22.24

200-Day Moving Average

22.46

Relative Strength Index (RSI)

49.70

Average Volume (3m)

1.34M

Immunome upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 11, 2026

Next Earnings Date

Nov 16, 2026

Ex-Dividend Date

―

Immunome as a current ratio of 14.69, with Debt / Equity ratio of 0.61%

Current Ratio

14.69

Quick Ratio

14.69

Debt to Market Cap

0.00

Net Debt to EBITDA

3.10

Interest Coverage Ratio

0.00

In the past 12 months, Immunome has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Immunome EV to EBITDA ratio is -8.33, with an EV/FCF ratio of -9.54.

EV to Sales

0.00

EV to EBITDA

-8.33

EV to Free Cash Flow

-9.54

EV to Operating Cash Flow

-10.01

Immunome has $520.00M in cash and marketable securities with $4.59M in debt, giving a net cash position of $515.41M billion.

Cash & Marketable Securities

$520.00M

Total Debt

$4.59M

Net Cash

$515.41M

Net Cash Per Share

$4.37

Tangible Book Value Per Share

$4.64

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin

0.00%

Operating Margin

0.00%

Pretax Margin

0.00%

Net Profit Margin

0.00%

EBITDA Margin

0.00%

EBIT Margin

0.00%

The average price target for Immunome is $35.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$35.33

Price Target Upside

81.01% Upside

Analyst Consensus

Strong Buy

Analyst Count

13

Revenue Growth Forecast

-100.00%

EPS Growth Forecast

18.12%

Smart Score

6

AI Score

47